Item 8.01. Other Events
The Company issued a press release regarding the enrollment of the first patient in the first Phase 3 clinical trial for the Company's lead product candidate, REL-1017. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits Exhibit No. Description 99.1 Press release datedDecember 7, 2020 1
© Edgar Online, source